ASH 2023 | Highlights in LR-MDS at the ASH 2023 meeting
Thomas Cluzeau
• 9 Dec 2023
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, outlines the areas of interest in lower-risk myelodysplastic syndromes (LR-MDS) at the annual ASH meeting in 2023. Dr Cluzeau shares his excitement regarding the three Phase III trials presented at the meeting: COMMANDS (NCT03682536), IMerge (NCT02598661), and MATTERHORN (NCT03263091). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Jazz Pharma, Abbvie, Novartis, Servier, BMS
Speakers Bureau: Jazz Pharma, Abbvie, Novartis, Servier, Incyte, BMS, Keros, Syros
